

Institutional Biosafety Committee - Regular Meeting

Thursday, October 02, 2025

Zoom

Meeting Minutes

VOTING MEMBERS PRESENT:	G. Babcock, K. Burns, G. Dean, M. Espinola, S. Kasper, R. Larson, E. Otten, E. Serafin, T. Rausch, F. Schaefer
VOTING MEMBERS NOT PRESENT:	S. Apewokin, J. Corcoran, D. Elsaesser, J. Yu
AD HOC MEMBERS/CONSULTANTS/GUESTS:	A. Anukanth, T. Gulley, J. Strasser
IBC STAFF:	D. Healy, B. Kesavalu

K. Burns convened the meeting at 12:00 p.m.

- I. Conflicts of Interest** – No conflicts were identified.
- II. Minutes** - Minutes from the previous IBC meeting (09/04/25) were approved (9: YES/0: NO/0: Abstained)

III. Old Business

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
1. 25-07-24-01	Mast	Renewal	BSL2	<i>in vitro</i> : HDM (hepatic tissue, hepatic tumor)
Status	- This protocol was voted on and approved on 09/04/25 pending modifications. - The PI has not addressed the issues.			

IV. New Business

A. Primary Protocols (1 protocol)

S. Kasper joined at 12:03 p.m. during review presentation

Dr. Raspe, joined at 12:55 pm during review presentation

IBC Protocol Number	PI	Type of Submission	IBC Items	
1. 25-09-10-01	Goldstick	New Clinical	mRNA (1195-P201)	
IBC Requests:	<u>IBC Form</u> 1. Provide BBP transcripts for clinical staff; 2. Section II. C. 1 - Gene - Enter "gp220, gH, gL, gp42, EBNA3A, and LMP2b antigens"; 3. Section III. A - Location #2 - Confirm that vaccine is prepared at the UC Medical Campus (MSB - Cincinnati) and then goes to a facility in Dayton (OH) for administration; 4. Section III. B - Check YES or NO for the use of biosafety cabinets; 5. Section III. B - In "Additional Information", indicate when a "glove box" (lab equipment) will be used and provide the type of needle safety device(s) (e.g., retractable needles or shielding needles); 6. Section V - For clarity, identify which REDCap reporting system the first sentence refers to.			
	Motion	Approve upon modifications addressing outlined issues.		
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

B. Secondary Protocols (3 protocols)

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
1. 25-09-18-01	Nannu Shankar	New	BSL1	<i>in vitro</i> : <i>Escherichia coli</i> (RG1), <i>Bacillus subtilis</i> , <i>Micrococcus luteus</i> , <i>Aspergillus niger</i> and MS2 bacteriophage
IBC Requests:	<u>Main Form – General Safety:</u> Section I. D - Will nebulizer be used in both rooms? If not, enter the rooms in different rows with indication of where nebulization will occur; Section III. A - Pipet - In addition to using containment equipment (i.e. BSC) there are safety measures that need to be followed while performing activities with potential of aerosol generation. For information on aerosol mitigation procedures, consult the eManual (link provided on the top of this section); Section III. A - Check "Other" and include the mitigation for the nebulizer; Section III. C - Whenever working in a lab, closed-toe shoes must be worn. Check the box in this regard. <u>Form B – Microbial/Infectious Agents</u> - Expand the "characteristics" for the different agents and provide their "strain".			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
2. 25-09-19-01	Herman	Renewal	BSL1	<i>in vivo</i> : AAV vector
IBC Requests:	- Lab staff need to complete their viral vector and BSC trainings; <u>Main Form – General Safety:</u> Section I. C - Include Ava Mussarra and ensure her training completion; Section I. D - RC C 207- Type/Function - "hood" should read "BSC" instead; Section II. C - Since the nature of transgene carried by AAV is not of concern, biosafety level can be downgraded to BSL1. Note, however, that after vector administration, animals will still need to be housed in biocontainment (ABSL2) for 72h; Section III. A - Pipet - For micropipets, tips should have cotton aerosol barriers. Include this info in this section field. <u>Form D – Biohazard in Animals:</u> Section III. C - Indicate where the Hamilton syringe is filled. Ventilation containment equipment (BSC or Fume Hood) should be used. Also, to reflect a previous statement (Main Form), check the "sharps containers" box and in "Additional Information" include what will be discarded in it.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
3. 25-09-17-01	Grillo	Renewal	BSL2	<u>in vitro</u> : AAV vector, HDM (cell lines, blood)
IBC Requests:	1. Lab staff need to complete their BBP, viral vector and BSC trainings; <u>Main Form – General Safety:</u> 2. Section I. B - If Secondary Contact does not have an office phone, add "N/A". <u>Form A – Recombinant or Synthetic Nucleic Acid:</u> 3. Section I - Genes #1 to #5 - In "Additional Information", indicate how gene is inhibited (e.g. shRNA, siRNA, miRNA, CRISPR/Cas9).			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

V. Protocol Updates August 28th to September 25th - 15 protocols

1. IBC# 25-05-20-01 - PI: Phoenix - Personnel
2. IBC# 24-06-18-02 - PI: Byrd - Personnel, Location
3. IBC# 23-02-14-02 - PI: Jose - Personnel
4. IBC# 23-12-19-01 - PI: Huang W- Personnel, Location
5. IBC# 23-10-12-01 - PI: Thompson T - Personnel
6. IBC# 25-06-04-01 - PI: Steele - Location
7. IBC# 24-01-09-01 - PI: Lander - Personnel, Location
8. IBC# 24-03-21-01 - PI: Sertorio - Personnel, Location
9. IBC# 23-04-20-01 - PI: Zhang P - Location
10. IBC# 23-04-21-01 - PI: Chella Krishnan - Personnel
11. IBC# 23-06-12-01 - PI: Oria - Personnel
12. IBC# 25-02-23-01 - PI: Grogan - Personnel
13. IBC# 24-09-11-01 - PI: Supp - Personnel
14. IBC# 22-09-14-01 - PI: Strobbsia - Location
15. IBC# 24-01-02-01 - PI: Waltz - Personnel

VI. Reports

- A. IBC/BSOf (M. Espinola)

BSOf is conducting inspections using tablets to input reports onsite and has successfully implemented the new system.

VII. Educational Materials/Updates

- A. [NIH Launches Initiative to Modernize and Strengthen Biosafety Oversight](#) NIH, September, 2025
- B. [Modernizing and Strengthening Oversight of Biosafety](#) NIH, September, 2025

K. Burns adjourned the meeting at 12:24 p.m.

